GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Orthovita, Inc. (VITA) [hlAlert]

Rating:
Buy VITA
down 11.79 %

Orthovita, Inc. (VITA) rated Buy with price target $5 by Maxim Group

Posted on: Wednesday,  Jul 21, 2010  8:25 AM ET by Maxim Group

Maxim Group rated Buy Orthovita, Inc. (NASDAQ: VITA) on 07/21/2010. Previously Maxim Group rated Buy Orthovita, Inc. (NASDAQ: VITA) on 04/06/2010.,
when the stock price was $4.41. Since then, Orthovita, Inc. has lost 11.79% as of 06/27/2011's recent price of $3.89.
If you would have followed the previous Maxim Group's recommendation on VITA, you would have lost 11.79% of your investment in 447 days.

Orthovita, Inc. (Orthovita) is an orthobiologics and biosurgery company, which develops and markets medical devices. The orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone. The biosurgery platform offers products for controlling intra-operative bleeding, also known as hemostasis. The Company?s fusion and regeneration products are based on its VITOSS Bone Graft Substitute technology and address the non-structural bone graft market with synthetic, bioactive alternatives to patient- and cadaver-derived bone tissue. Its CORTOSS Bone Augmentation Material, an injectable, polymer composite, which mimics the structural characteristics of human bone, provides the basis for its fixation portfolio. Orthovita?s hemostasis portfolio includes VITAGEL Surgical Hemostat, a collagen-based matrix that controls bleeding and facilitates healing, and VITASURE Absorbable Hemostat, a plant-based product that can be deployed quickly throughout surgery.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/21/2010 8:25 AM Buy
None
1.89 5.00
as of 12/31/2010
1 Week up  6.34 %
1 Month up  9.54 %
3 Months down  -3.96 %
1 YTD up  15.34 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/6/2010 8:25 AM Buy
None
4.41 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy